KLOW
GHK-Cu + KPV + BPC-157 + TB-500, 80 mg vial
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
Community name for a four-peptide blend that joins GHK-Cu (copper-binding peptide, tied to skin and connective tissue research) with KPV (anti-inflammatory tripeptide), BPC-157 (studied in soft tissue repair) and TB-500 (synthetic fragment of thymosin beta-4, used in cell migration research). The standard vial discussed is 80 mg in total, with 50 mg of GHK-Cu and 10 mg of each of the other three. It is GLOW plus KPV — and KPV is precisely the reason most people cite for choosing KLOW.
Quick reference
- Reconstitution
- 3.0 mL of bacteriostatic water in the 80 mg vial → about 26.7 mg/mL of the total blend.
- Measure
- 1 unit on a U-100 (0.01 mL) ≈ 267 mcg in total: ~167 mcg of GHK-Cu + ~33 mcg of each of the other three.
- Schedule
- The common plan uses subcutaneous injection 1×/day.
- Cycle
- Typical structure of 4–6 weeks on, 2–4 weeks off. Copper accumulation from GHK-Cu is what defines the off period.
- Status
- Not approved. No published trial has evaluated the four-peptide combination together.
Common Research-Context Titration
| Phase | Draw volume | Total blend delivered | GHK-Cu | KPV | BPC-157 | TB-500 |
|---|---|---|---|---|---|---|
| Weeks 1-2 | 7.5 units (0.075 mL) | ~2.0 mg total blend | ~1.25 mg | ~250 mcg | ~250 mcg | ~250 mcg |
| Weeks 3-4 | 15 units (0.15 mL) | ~4.0 mg total blend | ~2.5 mg | ~500 mcg | ~500 mcg | ~500 mcg |
| Weeks 5-8 | 22.5 units (0.225 mL) | ~6.0 mg total blend | ~3.75 mg | ~750 mcg | ~750 mcg | ~750 mcg |
| Weeks 9-12 (taper) | 15 units (0.15 mL) | ~4.0 mg total blend | ~2.5 mg | ~500 mcg | ~500 mcg | ~500 mcg |
Cycle Guidelines
| Approach | Duration | Off period | Notes |
|---|---|---|---|
| Standard | 4-6 weeks | 2–4 weeks | Most common cycle structure cited in the research-use community. |
| Extended | 8–12 weeks | 4 weeks | Reported with slow titration; longer cycles raise copper-accumulation concern from GHK-Cu. |
| Maximum extension | Up to 16 weeks | 4+ weeks | Reported anecdotally; no safety data supports continuous use beyond 12 weeks. |
Reconstitution guide
| BAC water added | Total concentration | GHK-Cu per unit (0.01 mL) | KPV / BPC-157 / TB-500 per unit |
|---|---|---|---|
| 2.0 mL | 40.0 mg/mL | ~250 mcg | ~50 mcg each |
| 3.0 mL (most common) | 26.7 mg/mL | ~167 mcg | ~33 mcg each |
| 4.0 mL | 20.0 mg/mL | ~125 mcg | ~25 mcg each |
KLOW vs GLOW vs Wolverine Stack
| Feature | Wolverine Stack | GLOW Stack | KLOW Blend |
|---|---|---|---|
| Components | BPC-157 + TB-500 | GHK-Cu + BPC-157 + TB-500 | GHK-Cu + KPV + BPC-157 + TB-500 |
| Total vial mass (typical) | 10-20 mg | 70 mg | 80 mg |
| Main research focus | Soft-tissue repair | Skin + tissue + recovery | Skin + tissue + anti-inflammatory |
| Adds KPV (anti-inflammatory) | No | No | Yes |
| Adds GHK-Cu (collagen / gene expression) | No | Yes | Yes |
| Number of injections | 1 | 1 | 1 |
KPV Cycle Length Chart
| Community approach | Reported duration | Reported break | Evidence level |
|---|---|---|---|
| Shorter cycle | 4-6 weeks | 2–4 weeks | Common research-community pattern; no KLOW trial |
| Extended cycle | 8–12 weeks | About 4 weeks | Reported in community protocols; no KLOW trial |
| Long extension | Up to 16 weeks | 4+ weeks | Anecdotal; very limited evidence for prolonged blend exposure |
Community KPV Cycles vs. Research Study Durations
| Source | Example duration | What was studied | What it tells us about KLOW |
|---|---|---|---|
| KLOW research community | 4-6 weeks | Four-peptide KLOW blend | Commonly reported cycle structure, not a controlled study |
| Extended KLOW community protocols | 8–12 weeks | Four-peptide KLOW blend | Shows how longer cycles are discussed, not that they are proven |
| Longer anecdotal KLOW protocols | Up to 16 weeks | Four-peptide KLOW blend | Anecdotal only; long-term blend data are lacking |
| GHK-Cu research | Up to about 12 weeks in human topical studies | GHK-Cu used on the skin | Supports GHK-Cu research, not an injectable KLOW cycle |
| KPV research | Days to weeks depending on the model | Mostly cell and animal inflammation models | Does not establish a KLOW cycle length |
| BPC-157 research | Varies widely by study | Mostly animal studies | No standard human cycle can be taken from this research |
| Thymosin beta-4 research | Days to weeks depending on the model | Full-length thymosin beta-4 in many studies | Does not establish a TB-500 or KLOW cycle |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.